These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19021723)

  • 1. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
    Biehn SE; Moore DT; Voorhees PM; Garcia RA; Lehman MJ; Dees EC; Orlowski RZ
    Ann Hematol; 2007 Mar; 86(3):211-6. PubMed ID: 17146676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
    J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
    Manochakian R; Miller KC; Chanan-Khan AA
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):266-71. PubMed ID: 17324333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
    Ataergin S; Arpaci F; Kaya A; Cetin T; Gunhan O
    Am J Hematol; 2006 Dec; 81(12):987-8. PubMed ID: 16888783
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Kropff MH; Bisping G; Wenning D; Volpert S; Tchinda J; Berdel WE; Kienast J
    Leuk Res; 2005 May; 29(5):587-90. PubMed ID: 15755512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
    Bladé J; Sonneveld P; San Miguel JF; Sutherland HJ; Hajek R; Nagler A; Spencer A; Robak T; Cibeira MT; Zhuang SH; Harousseau JL; Orlowski RZ;
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):352-5. PubMed ID: 19064400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
    Gozzetti A; Fabbri A; Oliva S; Marchini E; Bocchia M; Defina M; Lauria F
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):68-72. PubMed ID: 20223732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
    Popat R; Oakervee HE; Hallam S; Curry N; Odeh L; Foot N; Esseltine DL; Drake M; Morris C; Cavenagh JD
    Br J Haematol; 2008 May; 141(4):512-6. PubMed ID: 18371113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
    Chanan-Khan A; Miller KC; Musial L; Padmanabhan S; Yu J; Ailawadhi S; Sher T; Mohr A; Bernstein ZP; Barcos M; Patel M; Iancu D; Lee K; Czuczman MS
    Leuk Lymphoma; 2009 Jul; 50(7):1096-101. PubMed ID: 19479618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 19. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience.
    Warzocha K; Kraj M; Pogłód R; Kwaśniak B
    Acta Pol Pharm; 2008; 65(6):753-6. PubMed ID: 19172860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.